Abstract
The letter by Cesari et al.1 refers to yet unpublished data on the association between plasma adiponectin and prognostic outcome in patients with coronary heart disease (CHD). The authors exclusively focused on total adiponectin levels and did not consider its multimeric isoforms, such as the high-molecular weight isoform. In accordance with our study,2 adiponectin levels did not yield additional predictive value for secondary cardiovascular disease events in addition to traditional cardiovascular risk factors after appropriate adjustment for covariates and consequently may not be regarded as an independent biomarker for future risk in patients with prevalent CHD. However, we like to emphasize distinct differences regarding patient selection and design of the two studies resulting in important consequences for data interpretation.